Table 3.
Variable | Coding | Univariate HR (95% CI) | p value | Multivariate HR (95% CI) | p value |
---|---|---|---|---|---|
RS | Fractionally ranked | 2.33 (1.73–3.14)* | <0.001 | 1.73 (1.21–2.47)* | 0.001 |
Nodal status | |||||
pN1-3 vs pN0 | 1.55 (1.11–2.15) | 0.009 | NS | ||
pN2-3 vs pN0-1 | 3.23 (2.11–4.94) | <0.001 | 2.24 (1.27-3.96) | 0.005 | |
pN3 vs pN0-2 | 6.35 (3.34–12.07) | <0.001 | 2.88 (1.27–6.52) | 0.011 | |
Tumour stage | pT2-4 vs pT1 | 1.77 (1.27–2.47) | 0.001 | 1.49 (1.04–2.15) | 0.04 |
Grade | |||||
Local assessment | Grade 3 vs grade 1/2 | 2.36 (1.69–3.29) | <0.001 | 1.68 (1.13–2.51) | 0.02 |
Central assessment | Grade 3 vs grade 1/2 | 2.47 (1.77–3.43) | <0.001 | 1.77 (1.18–2.67) | 0.01 |
Ki-67 (%), semi- quantitative | Fractionally ranked | 2.66 (1.88–3.75)* | <0.001 | NS | |
ER (%) | Fractionally ranked | 0.75 (0.53–1.05)* | 0.10 | NS | |
PR (%) | Fractionally ranked | 0.53 (0.39–0.72)* | <0.001 | NS | |
IHC4 | Fractionally ranked | 2.04 (1.47–2.83)* | <0.001 | NS |
* 75th to 25th percentile
CI confidence interval, ER oestrogen receptor, HR hazard ratio, NS nonsignificant, PR progesterone receptor, RS recurrence score
Significant p values are specified in bold